Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Jefferies Upgrades Vanda Pharmaceuticals (VNDA) to Buy; Giving Credit for Tasimelteon
February 14, 2013 6:57 AM ESTJefferies upgraded Vanda Pharmaceuticals (NASDAQ: VNDA) from Hold to Buy with a price target of $6.00 (from $3.50).
The firm comments, "We're finally giving credit for tasimelteon given 1) surprisingly good recent Non24 Ph.3 data w/clinical sleep efficacy which likely improves FDA receptivity, 2) orphan pricing not... More
